Trial reportJournal of acquired immune deficiency syndromes (1999)2011
Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone.
Trial report in Journal of acquired immune deficiency syndromes (1999), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00263458 (Integrating Buprenorphine Into the SFGH AIDS Program), which is not on this map. Cited by 57 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Integrating Buprenorphine Into the SFGH AIDS Program (Patient Evaluation Study)
Who cites it
57 citing papers in PubMed, 4 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Integration of care for HIV and opioid use disorder.AIDS (London, England) · 2019Pooled it
- Primary care models for treating opioid use disorders: What actually works? A systematic review.PloS one · 2017Pooled it
- Retention in medication-assisted treatment for opiate dependence: A systematic review.Journal of addictive diseases · 2016Pooled it
- Representation of women and pregnant women in HIV research: a limited systematic review.PloS one · 2013Pooled it
- Integrating Methadone Services Into Primary Care in Ukraine: Two-Year Outcomes From a Randomized Trial.Annals of internal medicine · 2026Trial
- HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial.Addiction (Abingdon, England) · 2022Trial
- Trial
- Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial.AIDS and behavior · 2019Trial
- Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial.Addiction (Abingdon, England) · 2017Trial
- Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058.Journal of acquired immune deficiency syndromes (1999) · 2015Trial
- A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine.The American journal of medicine · 2013Trial
- Project RETAIN: Providing Integrated Care for People With HIV Who Use Cocaine.Open forum infectious diseases · 2025Article
- Rationale and design of a randomized clinical trial of integrated eHealth for PrEP and medications for opioid use disorders for women in the criminal legal system. The Athena study.Addiction science & clinical practice · 2025Article
- Perspectives on unhealthy alcohol use among men who have sex with men prescribed HIV pre-exposure prophylaxis: A qualitative study.Preventive medicine reports · 2024Article
- Substance Use Treatment Utilization Among Women With and Without Human Immunodeficiency Virus.Open forum infectious diseases · 2023Article
- Interventions for Integrating Behavioral Health Services Into HIV Clinical Care: A Narrative Review.Open forum infectious diseases · 2022Review
- Practices, attitudes, and confidence related to tobacco treatment interventions in HIV clinics: a multisite cross-sectional survey.Translational behavioral medicine · 2022Article
- Association of Bupropion, Naltrexone, and Opioid Agonist Treatment With Stimulant-Related Admissions Among People With Opioid Use Disorder: A Case-Crossover Analysis.The Journal of clinical psychiatry · 2022Article
- Essential components of physician health program monitoring for substance use disorder: A survey of participants 5 years post successful program completion.The American journal on addictions · 2022Article
- Buprenorphine reverses neurocognitive impairment in EcoHIV infected mice: A potential therapy for HIV-NCI.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 9 institutions in 1 country.
Funding
Abstract
backgroundBuprenorphine/naloxone allows the integration of opioid dependence and HIV treatment.
methodsWe conducted a prospective study in HIV-infected opioid-dependent patients to investigate the impact of buprenorphine/naloxone treatment on drug use. Self-report and chart review assessments were conducted every 3 months (quarters 1-4) for 1 year. Outcomes were buprenorphine/naloxone treatment retention, drug use, and addiction treatment processes.
resultsAmong 303 patients enrolled between July 2005 and December 2007, retention in buprenorphine/naloxone treatment was 74%, 67%, 59%, and 49% during Quarters 1, 2, 3, and 4, respectively. Past 30-day illicit opioid use decreased from 84% of patients at baseline to 42% in retained patients over the year. Patients were 52% less likely to use illicit opioids for each quarter in treatment (Odds ratio = 0.66; 95% CI: 0.61 to 0.72). Buprenorphine/naloxone doses and office visits approximated guidelines published by the United States Department of Health and Human Services. Urine toxicology monitoring was less frequent than recommended.
conclusionsBuprenorphine/naloxone provided in HIV treatment settings can decrease opioid use. Strategies are needed to improve retention and address ongoing drug use in this treatment population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.